SAN DIEGO, CA, USA I January 20, 2016 I AmpliPhi Biosciences Corporation (APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
“This is a key step in the development of a novel therapy to treat an extremely under-served population that exacts a significant financial toll on the healthcare system and the economy,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “Each year, nearly 13 percent of the U.S. population suffers from CRS, resulting in a productivity loss of over $10,000 per person, for a total annual loss in the United States of more than $350 billion. Our goal is to develop a better treatment for this common condition in order to alleviate tremendous suffering, especially in the estimated 2.6 million CRS patients who fail to respond to standard antibiotic treatment and resort to endoscopic surgery, yet continue to be plagued by the disease.”
AmpliPhi’s Phase 1 clinical trial is enrolling patients with CRS – defined as serious, often debilitating infection and inflammation of the nose and sinuses lasting 12 weeks or more – who have not responded to surgery and are infected with S. aureus. AmpliPhi expects to complete enrollment of the trial by the end of the first half of 2016.
“We are confident in our bacteriophage-based approach to treating infection in CRS patients, and we are grateful to our partners at University of Adelaide’s Queen Elizabeth Hospital and Flinders University for their dedication and commitment to moving this important research forward,” continued Mr. Salka.
For more information, visit www.ampliphibio.com.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to advance bacteriophage-based therapies.
About Bacteriophage
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
SOURCE: AmpliPhi Biosciences
Post Views: 41
SAN DIEGO, CA, USA I January 20, 2016 I AmpliPhi Biosciences Corporation (APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.
“This is a key step in the development of a novel therapy to treat an extremely under-served population that exacts a significant financial toll on the healthcare system and the economy,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “Each year, nearly 13 percent of the U.S. population suffers from CRS, resulting in a productivity loss of over $10,000 per person, for a total annual loss in the United States of more than $350 billion. Our goal is to develop a better treatment for this common condition in order to alleviate tremendous suffering, especially in the estimated 2.6 million CRS patients who fail to respond to standard antibiotic treatment and resort to endoscopic surgery, yet continue to be plagued by the disease.”
AmpliPhi’s Phase 1 clinical trial is enrolling patients with CRS – defined as serious, often debilitating infection and inflammation of the nose and sinuses lasting 12 weeks or more – who have not responded to surgery and are infected with S. aureus. AmpliPhi expects to complete enrollment of the trial by the end of the first half of 2016.
“We are confident in our bacteriophage-based approach to treating infection in CRS patients, and we are grateful to our partners at University of Adelaide’s Queen Elizabeth Hospital and Flinders University for their dedication and commitment to moving this important research forward,” continued Mr. Salka.
For more information, visit www.ampliphibio.com.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to advance bacteriophage-based therapies.
About Bacteriophage
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
SOURCE: AmpliPhi Biosciences
Post Views: 41
